|Bid||72.54 x 100|
|Ask||72.71 x 100|
|Day's Range||72.08 - 72.96|
|52 Week Range||63.76 - 82.10|
|PE Ratio (TTM)||7.67|
|Dividend & Yield||2.08 (2.88%)|
|1y Target Est||N/A|
Gilead Sciences (GILD) has gained 13% during the past three months as investors have started to bet that the beaten-down biotech stock has finally found a bottom. The iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.1% to $303.67.
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.